The research, led by James M. Hennegan and colleagues at the University of Southampton, focused on Fc gamma receptor IIb, the only inhibitory member of the Fc gamma receptor family that is conserved across species. These receptors normally serve as molecular sentinels of the immune system, binding the Fc domain of IgG antibodies and calibrating immune cell responses through a balance of activating and inhibitory signals. FcγRIIb restrains immune activation via its immunoreceptor tyrosine-based inhibitory motif, or ITIM, which recruits intracellular phosphatases when engaged. Crucially, the receptor is not confined to the periphery. Previous work has documented its expression on both neuronal and microglial membranes within the central nervous system, particularly under conditions of proteopathic stress, and earlier in vitro studies had shown that fibrillar alpha-synuclein binds directly to FcγRIIb, triggering downstream SHP-1/2-c-Src signalling that facilitates the protein’s internalisation.

What remained unresolved was whether this receptor genuinely governs alpha-synuclein spread in a living brain, rather than merely in a culture dish. To answer this question, the team turned to the preformed fibril, or PFF, model of synucleinopathy, in which synthetic fibrils of recombinant human alpha-synuclein are injected into the dorsal striatum of mice. The fibrils, fragmented by sonication into particles smaller than 50 nanometres and validated by transmission electron microscopy and Thioflavin-T fluorimetry, seed the aggregation of the brain’s own alpha-synuclein, generating Lewy body-like pathology that spreads along anatomically connected circuits in a manner that closely mirrors the human disease. The researchers compared wild-type C57BL/6 mice with mice in which the Fcgr2b gene had been deleted, and confirmed at both the RNA and protein levels that the knockout abolished receptor expression in the brain and spleen without altering other Fc gamma receptor family members or the mice’s own production of alpha-synuclein.

The results were striking. In primary cortical neurons cultured from embryonic tissue, exposure to preformed fibrils produced abundant phosphorylated alpha-synuclein, the pathological modification found at serine 129 that defines Lewy bodies, in wild-type cultures. Neurons lacking FcγRII showed an 88 percent reduction in this pathological staining, with far fewer inclusions in both the cell bodies and the neuritic arbours. When the team moved into living animals, injecting fibrils unilaterally into the striatum, the difference was even more dramatic. Thirty days after injection, wild-type mice had already developed robust phosphorylated alpha-synuclein pathology in the ipsilateral substantia nigra pars compacta, whereas knockout mice showed a near-complete absence of staining. By ninety days, wild-type brains were riddled with inclusions across the prefrontal cortex, primary motor cortex, entorhinal cortex, amygdala and substantia nigra, with muted deposition appearing even in the contralateral hemisphere, consistent with trans-hemispheric propagation.

The knockout mice were largely spared this anatomical cascade. Quantitative image analysis revealed reductions in pathological burden ranging from more than 70 percent in the ipsilateral substantia nigra to nearly 99 percent in the prefrontal and motor cortices, indicating that the receptor is not merely permissive but fundamental for efficient seeding and trans-neuronal propagation of the pathology along synaptically connected pathways. Distribution maps generated from the immunohistochemical data visualised the stark divergence between the two genotypes, with the wild-type hemisphere dotted with pathological signal and the knockout hemisphere almost clean. Control injections of monomeric, non-fibrillar alpha-synuclein produced no pathology in either genotype, confirming the specificity of the fibril-seeding response.

The protective effect extended beyond protein aggregation to the neurons themselves. Neuroinflammation is a central component of Parkinson’s pathogenesis, and in wild-type mice the fibril injection provoked a pronounced rise in microglial density, marked by increased Iba1 staining, and elevated expression of FcγRI, the high-affinity IgG receptor that appears on activated microglia. In knockout mice, this response was substantially blunted, with roughly a 72 percent reduction in Iba1-positive microglial density and a 29 percent decrease in FcγRI expression in the injected striatum at ninety days. The authors interpret this dampened gliosis as a secondary consequence of the reduced alpha-synuclein burden, suggesting that the receptor’s primary contribution to disease may be neuron-intrinsic, with impaired fibril internalisation limiting the downstream activation of glial cells.

Most importantly from a therapeutic standpoint, the loss of FcγRII preserved the nigrostriatal dopaminergic system. Wild-type mice injected with fibrils showed a marked reduction in tyrosine hydroxylase-positive fibre density in the dorsal striatum and a significant loss of dopamine neuron cell bodies in the substantia nigra by ninety days, the classic signature of progressive neurodegeneration in this model. Knockout mice maintained fibre density and neuronal counts equivalent to monomer-injected controls at both time points. Behavioural testing, conducted monthly before the animals were killed, suggested functional correlates of this protection: wild-type fibril-injected mice displayed reduced locomotor activity and exploratory drive in the open field and increased descent latency in the pole test, while knockout mice performed normally across all paradigms. The authors caution that the small cohort sizes render these behavioural findings suggestive rather than definitive, but their directionality aligns with the histological preservation.

To translate these genetic findings into a pharmacological strategy, the team exploited transgenic mice expressing human FcγRIIb and tested two monoclonal antibodies, BI-1206 and BI-1607, that selectively antagonise the human receptor. One antibody carried a wild-type Fc domain, while the other incorporated an N297Q substitution rendering it Fc-null, allowing the researchers to distinguish effects of receptor blockade itself from those mediated by Fc-driven engagement of activating Fc gamma receptors on immune cells. The antibodies were co-injected intracranially with the fibrils and supplemented with systemic dosing at 10 milligrams per kilogram to maintain circulating levels. Thirty days later, both antibody formats had produced a roughly 90 percent decrease in phosphorylated alpha-synuclein burden in the striatum and substantia nigra relative to an isotype control, with comparable efficacy between the Fc-wild-type and Fc-null variants. This equivalence suggests that blockade works predominantly through steric interference with the fibril-binding interface on the receptor, preventing alpha-synuclein uptake and pathological templating at the injection site before spread can begin.

The implications reach well beyond the laboratory. The antibodies used in this study are already advancing through oncology clinical trials, where FcγRIIb-directed therapeutics are being evaluated in CD32b-positive B-cell lymphomas, establishing a safety, tolerability and pharmacodynamic footprint that could accelerate repurposing toward neurodegenerative indications. Because the strategy targets the cellular entry route for fibrils rather than the protein aggregates themselves, it offers a mechanistically distinct complement to conventional anti-alpha-synuclein immunotherapies, which have struggled in clinical trials. Other receptors implicated in alpha-synuclein uptake, including LAG3, APLP1, the alpha-3 subunit of the sodium-potassium ATPase and connexin 32, suggest that fibrils may engage multiple overlapping entry pathways, but the magnitude of protection seen here indicates FcγRIIb is an especially influential conduit.

The authors are careful to note the limitations of the work. The initial knockout experiments used only male animals, cohort sizes were small, and tyrosine hydroxylase staining alone cannot distinguish frank neuronal loss from reduced expression or dysfunction without an independent pan-neuronal counterstain. The prophylactic antibody paradigm also does not address therapeutic intervention once pathology is established, and intracerebral delivery does not recapitulate the pharmacokinetics of systemic administration. Nevertheless, the convergence of genetic deletion and antibody blockade on the same outcome, a profound impairment of alpha-synuclein seeding, propagation and neurotoxicity in vivo, marks FcγRIIb as a pivotal and druggable regulator of synucleinopathy, and raises the tangible prospect that a receptor once studied for its role in immune regulation and cancer immunotherapy may become a target for slowing the progression of Parkinson’s disease.

Subject of Research: The role of the FcγRIIb receptor in alpha-synuclein propagation and its blockade as a therapeutic strategy for Parkinson's disease

Article Title: Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo

Article References: Hennegan, J. M., Hurley, M. J., Colley, M., Cox, K. L., Douglas, L. R., Duriez, P. J., Oldham, R. J., Cragg, M. S., Frendéus, B., Roghanian, A., & Teeling, J. L. (2026). Deletion or immunotherapeutic blockade of FcγRIIb (CD32b) impairs α-Syn propagation in vivo. Acta Neuropathologica, 152(1), Article 40. https://doi.org/10.1007/s00401-026-03082-7

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03082-7

Keywords: Parkinson's disease, alpha-synuclein, FcγRIIb, CD32b, preformed fibrils, neurodegeneration, monoclonal antibodies, microglia, substantia nigra, prion-like propagation, immunotherapy, synucleinopathy

Alpha-synuclein is a small, presynaptic protein that misfolds and aggregates into insoluble fibrils in a family of disorders collectively known as synucleinopathies. These include Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, as well as rare conditions such as pure autonomic failure. Although each of these disorders features alpha-synuclein inclusions, the aggregates differ in their ultrastructure, cellular location, and molecular conformations. In Lewy body diseases, the protein accumulates inside neurons as Lewy bodies and Lewy neurites, whereas in multiple system atrophy the aggregates form predominantly within oligodendrocytes, the myelin-producing glial cells of the central nervous system, as glial cytoplasmic inclusions. These structural and cell-type differences have profound consequences for imaging, because a ligand that recognizes one conformational strain of aggregated alpha-synuclein may not recognize another.

Positron emission tomography offers a noninvasive window into the molecular pathology of the living brain. A radiolabeled tracer is injected intravenously, crosses the blood-brain barrier, and binds to its molecular target; the scanner then maps the distribution of the signal over time. For amyloid-beta and tau, the hallmark proteins of Alzheimer’s disease, this strategy has been translated into clinically approved tracers that transformed both research and patient care. Alpha-synuclein has proved far more difficult. The protein is predominantly intracellular, so any tracer must enter neurons in sufficient quantity, bind specifically to the aggregated form rather than the soluble form, and avoid off-target binding to the abundant non-neuronal proteins that populate brain tissue. Several candidate tracers have reached human studies in recent years, but none has achieved the sensitivity and specificity needed for reliable clinical or research use.

The development path for any PET tracer runs through postmortem validation. Before a compound is labeled with a positron-emitting isotope such as carbon-11 or fluorine-18 and administered to patients, it is typically labeled with tritium, a low-energy beta emitter ideal for high-resolution autoradiography on tissue sections. Tritium autoradiography allows researchers to test whether a candidate ligand binds to authentic human pathology, how densely it labels the characteristic lesions, and whether that signal can be displaced by excess unlabeled compound, which demonstrates binding specificity. It also reveals off-target binding to unrelated structures such as neuromelanin, iron deposits, or monoamine oxidase enzymes, pitfalls that have derailed previous alpha-synuclein tracer candidates.

Against this backdrop, ³H-M503-1619 delivers a meaningful result: in human postmortem tissue from Lewy body disease cases, the ligand captures alpha-synuclein aggregates, providing direct evidence that the compound recognizes the authentic pathological substrate in patient brain rather than merely fibrils grown in a test tube. Autoradiographic binding to postmortem tissue is widely regarded as one of the most demanding benchmarks for a tracer candidate, because human pathology is heterogeneous, densely interwoven with comorbid pathologies such as amyloid-beta and tau, and embedded in tissue chemistry that no cell culture model fully reproduces. A ligand that survives this test has cleared one of the essential hurdles on the road to human PET imaging.

The negative finding in multiple system atrophy tissue is equally consequential, and it cuts in two directions at once. On one hand, it means that ³H-M503-1619, and by extension any PET tracer built on the same scaffold, would not be suitable for imaging the glial cytoplasmic inclusions that define multiple system atrophy. Distinguishing multiple system atrophy from Parkinson’s disease during life remains a major clinical challenge, particularly in the early stages when symptoms overlap and an accurate diagnosis changes management, prognosis, and eligibility for disease-modifying trials. A tracer that binds one synucleinopathy but not another cannot serve as a universal synuclein imaging tool.

On the other hand, the differential binding is scientifically informative. It demonstrates that the ligand recognizes a conformational feature of aggregated alpha-synuclein that is shared across Lewy body diseases but absent, occluded, or structurally different in multiple system atrophy inclusions. This is consistent with a growing body of evidence from cryo-electron microscopy and seeding studies showing that alpha-synuclein fibrils adopt distinct strain conformations in different diseases. In this sense, a tracer with selective binding is not a failure but a probe: its signal can, in principle, help discriminate between molecular subtypes of synucleinopathy, informing differential diagnosis and enabling stratification of patients in clinical trials of therapies that target specific aggregate morphologies.

The distinction between Lewy body diseases and multiple system atrophy also matters for therapy development. The past few years have seen multiple phase-two trials of alpha-synuclein immunotherapies and aggregation inhibitors in Parkinson’s disease, with results that have been disappointing or ambiguous. A recurring critique of those trials is the absence of a target-engagement biomarker: researchers could not confirm that the experimental drug reached and affected brain alpha-synuclein, nor could they confirm that every enrolled participant actually had significant brain alpha-synuclein pathology. A validated PET tracer would address both gaps, allowing dose selection based on observed target engagement and enriching trial cohorts with patients whose disease biology matches the therapeutic mechanism. The present result advances that objective specifically for Lewy body disease, where the ligand shows binding.

Several caveats temper the enthusiasm. Autoradiography with a tritium ligand measures binding affinity and regional distribution in tissue, but it does not establish the pharmacokinetic properties a PET tracer requires, including rapid brain entry and clearance, metabolic stability, negligible binding to peripheral sources of signal, and a favorable radiation dosimetry profile. Nor does postmortem binding establish that the signal-to-noise ratio achievable in a living scanner will suffice to detect the sparse, early-stage Lewy pathology that clinicians would most want to see. Many compounds that performed well in autoradiography have faltered at the human PET stage for reasons of kinetics or nonspecific white matter signal. The translation of M503-1619 to a fluorine-18 or carbon-11 radiotracer, and its eventual evaluation in human volunteers and patients, remains the decisive test.

Even so, the study contributes a scarce commodity to the field: a chemically defined ligand with demonstrated, selective binding to the alpha-synuclein pathology of human Lewy body disease tissue and a documented lack of binding to multiple system atrophy inclusions. As candidate tracers accumulate and are compared head to head on the same tissue archives, the field moves closer to the goal that has eluded it for two decades — a routine molecular imaging test for synucleinopathy that can support earlier diagnosis, differential diagnosis, objective tracking of disease progression, and mechanistically informed clinical trials. Whether ³H-M503-1619 becomes that tracer or a stepping stone toward it, the work sharpens the growing recognition that alpha-synuclein imaging must ultimately account for the distinct molecular strains that give synucleinopathies their different clinical faces.

Subject of Research: Development and postmortem validation of the PET ligand ³H-M503-1619 for imaging alpha-synuclein aggregates in Lewy body disease and multiple system atrophy.

Article Title: New PET ligand 3H-M503-1619 captures α-synuclein in human postmortem LBDs but not in MSA tissue

Article References: Saturnino Guarino, D., Crosby, J.-G., Sessions, Z. L., Dhavale, D. D., Robinson, J. L., Schuck, T., Lee, E. B., Kotzbauer, P. T., Luk, K. C., Lee, V. M.-Y., & Mach, R. H. (2026). New PET ligand 3H-M503-1619 captures α-synuclein in human postmortem LBDs but not in MSA tissue. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01564-9

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01564-9

Keywords: alpha-synuclein, PET imaging, Lewy body disease, multiple system atrophy, Parkinson's disease, tritium autoradiography, radioligand, synucleinopathy, postmortem brain tissue, neurodegeneration, biomarkers, tracer development

The researchers, led by Caoimhe Morley and Christos Proukakis, built on their earlier finding that somatic copy number gains of SNCA, the gene encoding alpha-synuclein, occur in the brains of people with synucleinopathies. In their new study, published in Acta Neuropathologica, they asked whether these gains arise specifically in oligodendrocytes, whether they cluster in the brain regions most damaged by the disease, and whether they correlate with the pathological inclusions that define it. Their strategy hinged on a technically demanding hybrid method that combines fluorescent in situ hybridisation, or FISH, with immunofluorescence, applied not to tissue sections but to suspensions of individual nuclei isolated from fresh-frozen post-mortem brain tissue.

The methodological choice matters. Working on sections makes it nearly impossible to reliably detect copy number losses, because slicing the tissue can truncate FISH signals and mimic a missing gene copy. Isolating nuclei eliminates this artefact while preserving alpha-synuclein inclusions, which in multiple system atrophy often sit in perinuclear or nuclear positions and remain attached to the nuclei during preparation. Each nucleus could therefore be interrogated on several axes simultaneously: the number of SNCA copies it carried, whether it belonged to the oligodendrocyte lineage as marked by the transcription factor SOX10, and whether it harboured an alpha-synuclein inclusion. The team analysed tissue from the putamen, cerebellum and substantia nigra of 13 cases with the striatonigral degeneration subtype, 12 cases with the olivopontocerebellar atrophy subtype, and 15 controls from the Queen Square Brain Bank.

The results were striking. Somatic SNCA copy number variants, both gains and losses, were significantly more frequent in multiple system atrophy oligodendrocytes than in controls. Gains were enriched more than threefold, appearing in 6.3 percent of SOX10-positive oligodendrocytes compared with 2.0 percent in controls, while losses were present in 12.5 percent versus 7.4 percent, with both differences highly significant. Crucially, the gains were not randomly distributed. They concentrated in the regions preferentially devastated by each disease subtype: the putamen in striatonigral degeneration and the cerebellum in olivopontocerebellar atrophy, along with the substantia nigra in both. The analysis also showed that CNVs were preferentially enriched at the SNCA locus itself; a chromosome 7 reference probe displayed relative genomic stability, indicating a locus-specific phenomenon rather than wholesale genomic chaos.

The single-cell correlations provide the study’s most provocative evidence. In the preferentially affected region of each subtype, oligodendrocytes carrying a somatic SNCA gain were more than twice as likely to contain an alpha-synuclein inclusion as their neighbours with a normal copy number, an effect that vanished in less affected regions. At the regional level, the frequency of oligodendrocyte gains correlated significantly with the overall burden of glial inclusions. This dovetails with established biology: people who inherit extra copies of SNCA develop parkinsonism driven by chronic alpha-synuclein overproduction, with duplications causing later-onset disease and triplications causing aggressive early-onset forms. Mouse models engineered to overexpress human alpha-synuclein specifically in oligodendrocytes develop inclusion-like pathology, demyelination and neuroinflammation. The new data suggest that the same dosage logic operates cell by cell in the human disease brain, with gains locally pushing intracellular alpha-synuclein toward the aggregation threshold.

Perhaps the most clinically resonant finding is a correlation between copy number gain burden and disease onset. Cases carrying a higher average proportion of oligodendrocyte SNCA gains developed symptoms significantly earlier, with a Spearman correlation coefficient of minus 0.45 and a p-value of 0.03. No such relationship existed for gains in non-oligodendroglial cells or for losses. Moreover, within individual cases, the level of gains correlated across brain regions and between oligodendrocytes and other cell populations, hinting that some patients carry an intrinsic, case-wide propensity for SNCA mosaicism. This raises the possibility of an early clonal event, arising during development, that seeds descendant cells across multiple regions and predisposes the brain to alpha-synuclein aggregation decades later. Distinguishing this from a generalised susceptibility to SNCA instability will require deep single-cell whole-genome sequencing, which is only now approaching the necessary resolution.

The study also reported, for the first time in multiple system atrophy, somatic SNCA losses. These were elevated in both oligodendrocytes and other cells but told a different story. They showed no clear regional predilection matching each subtype’s pathology, associated with inclusions only in the substantia nigra, and showed no correlation with age of onset or disease duration. That pattern argues against a primary causal role. Unlike gains, germline losses of SNCA have never been linked to synucleinopathies, and mice lacking alpha-synuclein do not develop relevant neurodegenerative phenotypes. The authors instead propose that losses may arise secondarily as the disease progresses, through the mis-repair of DNA damage.

That hypothesis gains weight from the study’s final arm, an examination of DNA double-strand breaks using immunofluorescence for gamma H2AX, the phosphorylated histone that marks sites of breakage and repair. Across the sampled regions, the proportion of gamma H2AX-positive cells was significantly higher in multiple system atrophy than in controls, 4.9 versus 2.5 percent overall, and nearly fourfold higher within oligodendrocytes. The signal was stronger in the preferentially affected regions and, strikingly, present in 22.2 percent of inclusion-bearing cells versus 14.9 percent of inclusion-free ones. This mirrors recent reports in Lewy body diseases linking DNA damage to alpha-synuclein pathology. Because post-mitotic brain cells repair double-strand breaks through the error-prone non-homologous end joining pathway, unrepaired or mis-repaired breaks can generate deletions, potentially including SNCA itself. Yet the authors caution that more than three-quarters of inclusion-positive cells showed no evidence of breaks, and the temporal sequence of damage, aggregation and copy number change remains unresolved.

The findings do not paint copy number variation as a sole cause. Most inclusion-bearing oligodendrocytes carried a normal SNCA copy number, and individuals with inherited SNCA multiplications typically develop a Parkinson-like picture rather than full multiple system atrophy, suggesting that somatic gains act as one influential contributor among many, a first hit or modifier that lowers the threshold for aggregation within vulnerable glia. Cell-type-specific stress, environmental exposures, unidentified inherited variants and other somatic mutations, possibly including age-related clonal haematopoiesis recently associated with the disease, are likely to complete the picture. Even so, the work reframes the search for multiple system atrophy’s origins. The culprit may not lie in the genome everyone inherits, but in the mosaic of genomes that individual brain cells acquire across a lifetime, and in oligodendrocytes silently accumulating extra copies of the very gene whose protein will one day fill them with inclusions.

Subject of Research: Somatic SNCA copy number variation in oligodendrocytes and its role in multiple system atrophy pathogenesis

Article Title: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy

Article References: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy. (n.d.). https://doi.org/10.1007/s00401-026-03077-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03077-4

Keywords: multiple system atrophy, SNCA, alpha-synuclein, oligodendrocytes, somatic copy number variants, glial cytoplasmic inclusions, DNA double-strand breaks, gamma H2AX, fluorescent in situ hybridisation, genetic mosaicism, synucleinopathy, neurodegeneration